[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].

The aim of our investigation was to study the peculiarities of serum uric acid (UA) levels in patients with metabolic syndrome (MS) during 6 month therapy with metformin (MF), Rosiglitazone (RG) and their combination. 30 patients with MS (10 males, 20 females, mean age - 35,5+/-9,7 years) have been investigated by all parameters of MS and serum UA levels. Investigated group was divided into 3 subgroups of 10 patients: group 1 - patients on RG; group 2 - patients on MF; group 3 - patients on RG + 850-1000 mg of MF. Results of investigation showed that UA serum levels did not decrease significantly. However, the frequency of hyperuricemia decreased significantly. PPG, basal C-peptide, and HOMA-% IR also decreased significantly. Despite percentage reduction of BMI in group 3 (7,6%), decrease of UA and HOMA-IR was significantly higher in group 1 (18,2% and 37.0%, respectively). Correlation analysis showed that decrease of UA significantly correlated with BMI and HOMA-IR in the whole group (r=0.5674, p=0.001; r=0.5437, p=0.002; respectively); in group 1 - with HOMA-IR (r=0.5753, p=0.016); in group 3 - with BMI (r=0.7821, p<0.001). Obtained results showed that UA levels and hyperuricemia cases significantly decreased during insulin sensitizing therapy.

[Levels of uric acid in serum in patients with metabolic syndrome].

The aim of our investigation was to study the peculiarities of serum uric acid (UA) levels in patients with metabolic syndrome (MS) and without it, also correlations between UA and parameters of MS features. 41 patients (mean age - 37,8+/-13,7 years) have been investigated. MS was defined by definitions of WHO (2002), ATPIII and Society of Georgia Endocrinologists (SGE). Exclusion criterion served the gout. Levels of all parameters of MS features and serum UA have been determined. MS was diagnosed in 48,7% of cases. Study group consisted of these patients, and control group - patients without MS. Serum UA levels were significantly higher in the study group in comparison with the control (6,6+/-1,4 vs. 5,4+/-1,3 mg/dl, p=0,007; respectively). In main group the cases of hyperuricemia have been documented significantly frequently than in control (65,0% vs. 33,3%, p=0,043; respectively). Obtained results shown that UA levels significantly higher and hyperuricemia cases significantly frequent at MS, which have to be taking into account during symptomatic treatment of patients.